Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies
{{output}}
High heterogeneity and an immunosuppressive tumor microenvironment (TME) are the core therapeutic bottlenecks of digestive system tumors. Current monotherapies face prominent limitations: immune checkpoint inhibitors (ICIs) yield low overall response rates as ... ...
